Skip to main content
Oncotarget logoLink to Oncotarget
. 2017 Oct 24;8(58):98876–98886. doi: 10.18632/oncotarget.22016

Cutaneous melanoma primary site is linked to nevus density

Alejandro Martin-Gorgojo 1,#, Marta Llinares 2,#, Amaya Virós 3,4,#, Celia Requena 2, Zaida Garcia-Casado 5, Víctor Traves 6, Rajiv Kumar 7, Eduardo Nagore 2,8
PMCID: PMC5716774  PMID: 29228734

Abstract

There are at least two pathways driving cutaneous melanoma; one is linked to an inherent melanoma susceptibility to nevi development and the second to environmental cumulative ultraviolet light exposure. In this study, we examined the relation between nevus density, accrued sun damage and the site of primary melanoma excision.

In a series of 888 consecutive cutaneous melanoma patients, melanomas appearing in skin areas with a high relative nevus density were most prominent in men, with an elevated nevus count, at sites without solar elastosis, but with an epidemiological history of previous sunburn.

The present study associates melanoma development to sites with high nevus density. Our study supports more careful surveillance of body areas with increased nevus density in patients with high total body number of nevi, especially when they report a history of sunburns at these sites.

Keywords: melanoma, nevus, risk, sunburn, solar elastosis

INTRODUCTION

By studying risk behavior and epidemiological characteristics of melanoma patients, Whiteman et al. proposed a dual pathway to melanoma acquisition [1, 2]. One possible route to melanoma is the nevus-prone pathway, where intrinsic predisposition to melanocytic proliferation drives the presence of a high number of melanocytic benign and atypical nevi [3, 4]. On the other hand, a second path links the accumulation of cutaneous actinic damage throughout life, or excessive chronic or intermittent ultraviolet radiation (UVR) exposure, to melanoma [2]. Patients developing melanoma through this second pathway have typically fair skin and signs of chronic sun damage, other UVR-related non-melanoma skin cancers and the expression of p53 protein in the primary tumor [4].

Although the nevus-prone pathway underpins melanoma patients with multiple nevi, it is unclear whether the primary melanoma in this context is more likely to arise at sites where the number of nevi is highest [59]. Nevi are not distributed homogeneously on the body and their location can be influenced by genetic and environmental (UVR) factors, so we investigated whether the site of primary melanoma is related to the relative density of nevi on the cutaneous area where it arises. Here we present the clinical and epidemiological features of primary melanoma in relation to the nevus density at the site they develop, and investigate the care implications.

RESULTS

Out of 2052 patients included in the database, 1550 had newly diagnosed melanomas, and 1110 individuals had sporadic invasive cutaneous melanomas, of whom a total of 888 patients had sufficient data recorded to calculate both the total nevus density and the nevus density at the melanoma region. The characteristics of the studied population are detailed in Table 1.

Table 1. Total population and subgroup (divided following the nevi density on the melanoma area) description, and univariate (Chi-square) analyses results.

Variable Total(N=888) 0 nevus/m2(N=339) 1-15 nevi/m2(N=238) >15 nevi/m2(N=311) P(Pc)
N % N % N % N %
Age (mv: 0) <0.001(<0.001)
 -≤45 280 31.5 58 17.1 75 31.5 147 47.3
 -46-60 297 33.4 94 27.7 95 39.9 108 34.7
 ->60 311 35.0 187 55.2 68 28.6 56 18.0
Sex (mv: 1 [0.1%]) 0.009(0.135)
 -Male 433 48.8 148 43.8 112 47.1 173 55.6
 -Female 454 51.2 190 56.2 126 52.9 138 44.4
Location (mv: 0) <0.001(<0.001)
 -Head/neck 161 18.1 101 29.8 39 16.4 21 6.8
 -Upper limb 130 14.6 48 14.2 29 12.2 53 17.0
 -Trunk 358 40.3 42 12.4 121 50.8 195 62.7
 -Lower limb 186 20.9 101 29.8 49 20.6 36 11.6
 -Acral 53 6.0 47 13.9 0 0.0 6 1.9
Sun exposure at melanoma site (mv: 0) <0.001(<0.001)
 -None/rarely 73 8.2 51 15 9 3.8 13 4.2
 -Occasionally 640 72.1 180 53.1 181 76.1 279 89.7
 -Usually 175 19.7 108 31.9 48 20.2 19 6.1
Number of common nevi (mv: 0) <0.001(<0.001)
 - <20 590 66.4 323 95.3 196 82.4 71 22.8
 -20-50 161 18.1 9 2.7 34 14.3 118 37.9
 -51-100 92 10.4 4 1.2 8 3.4 80 25.7
 - >100 45 5.1 3 0.9 0 0.0 42 13.5
Total body nevi density (mv: 0) <0.001(<0.001)
 -<2.5 282 31.8 223 65.8 58 24.4 1 0.3
 -2.5-10.6 303 34.1 97 28.6 135 56.7 71 22.8
 - >10.6 303 34.1 19 5.6 45 18.9 239 76.8
Solar lentigines (mv: 12 [1.4%]) 0.198(1.0)
 -No 103 11.8 43 12.9 32 13.6 28 9.1
 -Yes 773 88.2 291 87.1 203 86.4 279 90.9
Solar lentigines on MM area (mv:6 [0.7%]) 0.025(0.375)
 -No 439 49.8 183 54.5 120 50.8 136 43.9
 -Yes 443 50.2 153 45.5 116 49.2 174 56.1
Severe sunburns (mv:1 [0.1%]) 0.005(0.075)
 -No 407 45.9 183 54.1 105 44.1 119 38.3
 -1-5 304 34.3 99 29.3 85 35.7 120 38.6
 -6-10 69 7.8 19 5.6 22 9.2 28 9.0
 - >10 107 12.1 37 10.9 26 10.9 44 14.1
Sunburns at MM area (mv: 10 [1.1%]) <0.001(<0.001)
 -No 276 31.4 158 47.3 55 23.2 63 20.5
 -Mild 359 40.9 114 34.1 115 48.5 130 42.3
 -Intense 243 27.7 62 18.6 67 28.3 114 37.1
Histological subtype (mv: 0) <0.001(<0.001)
 -LMM 97 10.9 67 19.8 20 8.4 10 3.2
 -SSM 581 65.4 175 51.6 174 73.1 232 74.6
 -NM 132 14.9 43 12.7 32 13.4 57 18.3
 -ALM 31 3.5 30 8.8 0 0.0 1 0.3
 -Other/NOS 47 5.3 24 7.1 12 5.0 11 3.5
Contiguous neval remnants (mv: 32 [3.6%]) <0.001(>0.001)
 -No 637 74.4 273 83.2 165 72.7 199 66.1
 -Yes 219 25.6 55 16.8 62 27.3 102 33.9
CSD (mv:=301 [33.9%]) <0.001(<0.001)
 -No 507 86.4 178 76.1 140 89.2 189 96.4
 -Yes 80 13.6 56 23.9 17 10.8 7 3.6
Stage (mv: 0) 0.958(1.0)
 -In situ 154 17.3 62 18.3 39 16.4 53 17.0
 -Local disease 617 69.5 230 67.8 170 71.4 217 69.8
 -Locoregional 115 13.0 46 13.6 29 12.2 40 12.9
 -Metastatic 2 0.2 1 0.3 0 0.0 1 0.3
Non-synonymous 0.032
MC1R variants (mv: 0) (0.480)
 -None 280 33.8 118 38.2 73 32.6 89 30.1
 -1 variant 332 40.0 118 38.2 101 45.1 113 38.2
 ->1 variant 217 26.2 73 23.6 50 22.3 94 31.8

mv: missing values.

CSD: severe chronic sun damage on the skin surrounding the melanoma.

P: p-value from Chi squared test.

Pc: p-value corrected by Bonferroni test.

When patients were grouped according to the nevus density at the melanoma region, a high nevus density was significantly associated with young age at presentation, a high total body nevus count and density, and presence of one or more non-synonymous MC1R variants. These patients more frequently presented the melanoma on the trunk and had a history of intermittent sun exposure where the patient recalled having had sunburns in the past. The tumor was mainly of the SSM subtype and presented without histological signs of chronic sun damage (absent solar elastosis, non-CSD) (Table 1).

When comparing patients classified by the site-specific relative nevus density, melanomas located on an area with a higher nevus density than the total body density occurred more frequently in patients who were men (53.3%), were 45 years of age or younger (39.1%) and had a high total body nevus density (49.1% had >10.6 nevi/m2). The frequency of patients with increased relative nevus density at melanoma site increased progressively with increase in total body nevus density; with 18.3%[50/273] in the group with <2.45 nevi/m2, 52.8%[160/303] in the group with 2.45-10.60 nevi/m2 and 69.2%[211/303] in the group with >10.60 nevi/m2. In addition, the SSM subtype tumors were more frequent (73.7% of patients), developed in intermittently sun-exposed areas (85% of patients), and the patients recalled having suffered sunburns. In our study 90% of patients recalled having suffered at least one sunburn at the site, with 35.7% remembering at least one severe, blistering sunburn. This epidemiological history was consistent with the presence of solar lentigines (58.2%) but absent solar elastosis with 93.5% of patients compared to 79.9% in the group with relative nevus density lower than or equal to the total body nevus density. The 32.8% of primary melanomas had an increased frequency of contiguous neval remnants compared to 18.8% in the group with low site-specific nevus density (Table 2). The age-adjusted multivariate analysis confirmed a high total body nevus density with 6.5X for third and 4.2X for second tertiles. The absence of solar elastosis at the primary melanoma site, and a past history of sunburns at the melanoma site were the relevant variables that significantly associated with the development of tumors in areas with a high relative nevus density (Table 3). Furthermore, we describe a progressive decrease in solar elastosis with increasing melanocyte count in melanoma patients (Figure 1).

Table 2. Characteristics of the groups defined by the relative nevi density on the melanoma area compared to the total body surface nevi density.

Nevi density on the MM area lower or equal to total body nevi density Nevi density on the MM area higher to total body nevi density
Variable N % N % P(Pc)
Age (mv: 0) <0.001
 -≤45 112 24.5 168 39.1 (<0.001)
 -46-60 139 30.3 158 36.7
 ->60 207 45.2 104 24.2
Sex (mv: 1 [0.1%]) 0.01
 -Male 204 44.6 229 53.3 (0.15)
 -Female 253 55.4 201 46.7
Location (mv: 0) <0.001
 -Head/neck 121 26.4 40 9.3 (<0.001)
 -Upper limb 61 13.3 69 16.0
 -Trunk 82 17.9 276 64.2
 -Lower limb 146 31.9 40 9.3
 -Acral 48 10.5 5 1.2
Sun exposure of melanoma site (mv: 0) <0.001
 -None/rarely 60 13.1 13 3.0 (<0.001)
 -Occasionally 272 59.4 368 85.6
 -Usually 126 27.5 49 11.4
Number of common nevi (mv: 0) <0.001
 - <20 372 81.2 218 50.7 (<0.001)
 -20-50 48 10.5 113 26.3
 -51-100 22 4.8 70 16.3
 - >100 16 3.5 29 6.7
Total body nevi density (mv: 0) <0.001
 -<2.5 223 48.7 50 13.7 (<0.001)
 -2.5-10.6 143 31.2 160 37.2
 - >10.6 92 20.1 211 49.1
Solar lentigines (mv: 12 [1.4%]) 0.679
 -No 55 12.2 48 11.3 (1.0)
 -Yes 396 87.8 377 88.7
Solar lentigines on MM area (mv:6 [0.7%]) <0.001
 -No 260 57.3 179 41.8 (<0.001)
 -Yes 194 42.7 249 58.2
Number of severe sunburns (mv:1[0.1%]) 0.123
 -No 224 49.0 183 42.6 (1.0)
 -1-5 151 33.0 153 35.6
 -6-10 28 6.1 41 9.5
 - >10 54 11.8 53 12.3
Sunburns at the MM area (mv: 10 [1.1%]) <0.001
 -No 195 43.1 81 10.0 (<0.001)
 -Mild 166 36.7 193 45.3
 -Intense 91 20.1 152 35.7
Histological subtype (mv: 0) <0.001
 -LMM 73 15.9 24 5.6 (<0.001)
 -SSM 264 57.6 317 73.7
 -NM 61 13.3 71 16.5
 -ALM 30 6.6 1 0.2
 -Other/NOS 30 6.6 17 4.0
Contiguous neval remnants (mv: 32 [3.6%]) <0.001
 -No 358 81.2 279 67.2 (<0.001)
 -Yes 83 18.8 136 32.8
CSD (mv:=301 [33.9%]) <0.001
 -No 247 79.9 260 93.5 (<0.001)
 -Yes 62 20.1 18 6.5
Stage (mv: 0) 0.986
 -In situ 80 17.5 74 17.2 (1.0)
 -Local disease 316 69.0 301 69.5
 -Locoregional 61 13.3 54 13.0
 -Metastatic 1 0.2 1 0.2
Non-synonymous MC1R variants (mv: 0) 0.181
 -None 155 36.7 125 30.7 (1.0)
 -1 variant 160 37.9 172 42.3
 ->1 variant 107 25.4 110 27.0

P: p-value by Chi-squared test.

Pc: p-value corrected by Bonferroni test.

Table 3. Age-adjusted multivariate regression model for the characteristics significantly associated to a site-specific relative nevus density higher than the total nevus density.

Variable OR 95% CI P
Female vs. male 0.5 0.4-0.8 0.002
Total body nevi density:
 -<2.5 Ref. Ref.
 -2.5-10.6 4.2 2.6-6.8 <0.001
 - >10.6 6.5 3.9-10.9 <0.001
Sunburns at melanoma area:
 -No Ref. Ref.
 -Mild 3.2 2.0-5.1 <0.001
 -Intense 3.9 2.3-6.6 <0.001
CSD
 -No Ref. Ref. 0.001
 -Yes 0.3 0.2-0.6

Ref: Reference.

Figure 1. Number of patients showing histological evidence of CSD according to the nevi density on the melanoma area.

Figure 1

DISCUSSION

In this study using data from 888 melanoma patients we describe the characteristics of melanomas according to total body nevus density and according to nevus density at the site of primary melanoma. Melanomas arising in areas with a high nevus density and the tumors developing in cutaneous areas with a site-specific relative nevus density greater than the total body nevus density are more frequently observed in men with a high total body nevus density and count. These tumors more likely arise in previously sunburned skin areas as recalled by the patient, and the peritumoral skin presents no histological signs of chronic sun damage.

Nevus density and total number of nevi have been known for decades to be an important risk factor to melanoma [1012]. Total nevus density has been linked to sun exposure [13], lighter phototypes, a history of sunburns in children [14, 15], melanomas with contiguous neval remnants [16], familial cases of dysplastic nevus syndrome and melanoma [17], genetic cell-cycle control factors [18, 19] such as the CDKN2A gene [20, 21] and others [22], as well as an absent p53 expression within melanoma tumor samples, which supports the divergent pathway model [1, 23]. Although the association between primary tumor site and nevus distribution has been noted this has not yet been studied in depth [2428] and, therefore, there are currently no clear recommendations regarding variations in regional anatomic or site-specific nevus density.

The present study is, to our knowledge, the first to assess subsets of patients specifically according to both absolute and site-specific relative nevus density in 888 prospectively recruited melanoma patients with inclusion of clinical, histological and genetic susceptibility factors. The data analysis has shown that patients presenting with a higher site-specific relative nevus density are more frequently male, younger, with a higher total body nevus density, a past history of sunburns on the melanoma area, and with histopathological findings showing no chronic sun damage.

Our findings link a higher nevus density at the melanoma area with younger patients, which could be associated to the progressively lower nevus count observed during ageing. Male sex has also proven to be an independent associated factor [24]. This could be due to the higher frequency of melanoma on the back and shoulders in males, areas with overall higher melanocytic nevi counts [3]. Additionally, men report different patterns of sun exposure and behavior [29]. In a similar manner, the SSM histological subtype may be associated to high nevus density due to its overall higher incidence and its well-established link to overall higher nevus counts [25]. We also found an increased frequency of contiguous neval remnants at sites of higher nevus density which could be justified by the inherent association of melanoma arising over a nevus, however this question has not been examined in detail.

Our data supports that patients with high overall nevi numbers have a significantly increased risk of presenting a melanoma in areas with a high relative nevus density [3, 25]. We hypothesize this observation could be due to either a site-specific higher melanocyte proliferation, to the influence of greater sun exposure at this area, or due to a combination of both factors. The strong link between nevus density, primary melanoma site and a prior history of sunburn or intermittent UVR exposure at the same site support the role of sun exposure as a trigger for melanoma development in an already predisposed area [3032]. The present findings suggest that areas with a high nevus density that have suffered mild or intense sunburns should be clinically examined more carefully, and should probably need to be more meticulously sun protected in order to prevent the increase in the number of nevi, an approach which has been proven especially useful in fair-skinned, freckle-prone patients [19].

By contrast, CSD melanomas are confirmed to arise more frequently on chronically sun-exposed areas -such as the head and neck- in patients with non-melanoma skin cancers and a low number of nevi [2, 33, 34]. These data further supports the divergent etiologic pathway model [2].

Importantly, we show that the higher the nevus density at a primary melanoma site, the less likely it is to present CSD. Using CSD as a surrogate marker of cumulative sun damage, our finding strengthens the idea that individuals with increased propensity (susceptibility) to nevus development require less total sun exposure to progress to melanoma. The gradual decline in CSD as the number of nevi increase in our patients supports the idea that the two main pathways for cutaneous melanoma are not mutually exclusive but complimentary, representing two ends of an etiopathological spectrum where a higher inherent nevus propensity requires less UVR cooperation, and in individuals with lower nevus density there is progressive increased UVR involvement for melanomagenesis.

An advantage of our study is that all patient data were collected prospectively, following homogeneous criteria, assessed by the same clinicians within a national tertiary reference center with a wide geographical catchment area. Thus, our cohort is a faithful extrapolation of Spanish melanoma patients. However, certain limitations may affect this study, such as its sample size, the inherent constraints associated to a retrospective approach and the intrinsic recall bias in the history of sunburns at the site of primary melanoma incidence, although the latter affects equally all the patients who did not know the purpose of the present study when providing this information.

In summary, we show that a higher nevus density at a given area increases the risk of developing melanoma at this site, particularly in male patients who have a high overall nevus density, a past personal history of sunburns at the site of melanoma. This is progressively and inversely correlated to histological evidence of chronic sun damage. Identifying these individuals at high-risk will help tailor surveillance and monitoring campaigns in the primary care setting.

MATERIALS AND METHODS

In this retrospective, observational study, data from the melanoma database of the Dermatology Department of the Instituto Valenciano de Oncologia (IVO), Valencia, Spain, were analyzed. This database, launched in 2000, has been regularly updated with data from all newly diagnosed and follow-up melanoma patients. Clinical, epidemiologic, and histological data are collected prospectively, including the medical history and physical examination of patients performed by interview by dermatologists with experience in melanoma management [29]. Specifically, nevus count was performed by an experienced dermatologist (E.N.) and included all unequivocal nevi (when appropriate this fact was assessed by dermoscopy) above 2 mm of diameter.

The present study was approved by our institution's Research Ethics Board. Informed consent was obtained from all participants.

Inclusion criteria were incident patients with invasive sporadic cutaneous melanoma, who had received definitive treatment at our institution between January 1, 2000, and December 31, 2014. Patients with extracutaneous melanomas and those with metastatic melanomas and unknown primary tumor were excluded.

The hypothesis of the study was that melanomas in patients with high number of total nevi develop mainly in areas with increased nevus density. Therefore, the primary outcome measure was the site-specific relative nevus density, which was defined as the ratio of the site specific nevus density to the total body nevus density for each person.

For the purpose of this study, we calculated the nevus density both according to overall skin surface and to the region where the melanoma had developed. Total body nevus density was calculated by dividing the number of common nevi greater than 2 mm in diameter by the body surface. This surface was defined according to the DuBois formula: (weight (kg)0.425) x (height (cm)0.725) x 0.007184- [35]. Nevus density at the melanoma region was calculated counting the number of nevi at the region where the melanoma presented and defining ‘region’ using Wallace's rule of nines to infer the proportion of total body surface: head (9% of the total body surface), upper limb (7% excluding the hand), hand (2%) anterior trunk (18%), posterior trunk (18%), lower limb (15% excluding the foot), foot (3%) [36]. Thereafter, three categories of nevus density at the melanoma area were defined by tertiles: 0 nevi/m2 (low density), 1-15 nevi/m2 (intermediate density) and >15 nevi/m2 (high density).

For the comparative analyses, the following variables were used:

1. Epidemiological variables: age (<45, 45-60, or >60 years), sex, melanoma location (head/neck, trunk, upper limb, lower limb, and acral locations).

2. Phenotypic traits: “photolocation” or melanoma location according to sun exposure patterns (rarely/non-exposed, occasionally exposed, usually exposed), number of common melanocytic nevi (<20, 20-50, 51-100 and >100), nevus density on the complete body surface (total number of nevi/square meters of body surface, further categorized according to tertiles into: <2.5, 2.5-10.6 and >10.6), presence of solar lentigines, and presence of solar lentigines at the melanoma area.

3. Environmental factors: past personal lifetime history of severe sunburns (none, 1-5, 6-10, >10), past personal history of sunburns at the melanoma site (none, mild, intense).

4. Histopathological criteria: melanoma subtype (superficial spreading melanoma [SSM], lentigo maligna melanoma [LMM], nodular melanoma [NM], acral lentiginous melanoma [ALM] or other/non-specified [Other/NOS]), contiguous neval remnants, solar elastosis (as a sign of cumulative sun-damage –[CSD] and categorized in CSD vs. non-CSD according to previous classification [37]), and stage (in situ, local disease, locorregional disease, metastatic disease). All slides were reviewed by the same pathologist to avoid interobservational bias.

3. Germline susceptibility: presence of any non-synonymous MC1R variants (Supplementary Table 1) determined by direct sequencing according to previously described methods and categorized into none, one or more than one variant [38].

We performed two independent comparisons. First, the aforementioned characteristics were compared between the three groups defined by the density of nevi within the melanoma primary site. Second, we compare the characteristics between the two groups defined by the site-specific relative nevus density: one group where the nevus density at the melanoma area was lower or equal to the total body nevus density (a ratio value less than or equal to one), and another in which it was higher (a ratio value greater than one).

The differences between the distributions of each variable in our groups were evaluated using Pearson's chi-square test. Odds ratios (OR) were calculated by univariate and age-adjusted stepwise forward multivariate logistic regression to assess the association of each variable to a site-specific relative nevus density higher than the total nevus density. All the statistical analyses were performed using the SPSS statistical package for Windows, version 20.0 (IBM Inc; Illinois, USA).

SUPPLEMENTARY MATERIALS FIGURES AND TABLES

oncotarget-08-98876-s001.pdf (1,000.8KB, pdf)

Footnotes

CONFLICTS OF INTEREST

The authors state no conflicts of interest.

FUNDING

This study has been supported partially by grant 2017-109-001 from the Universidad Católica de València and by grant PI15/01860 from the Fondo de Investigaciones Sanitarias del ISCIII. AV is funded by Wellcome Trust (110078/Z/15/Z).

REFERENCES

  • 1.Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer. 1998;77:843–848. doi: 10.1002/(sici)1097-0215(19980911)77:6<843::aid-ijc8>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 2.Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003;95:806–812. doi: 10.1093/jnci/95.11.806. [DOI] [PubMed] [Google Scholar]
  • 3.Chiarugi A, Quaglino P, Crocetti E, Nardini P, De Giorgi V, Borgognoni L, Brandani P, Gerlini G, Manganoni AM, Bernengo MG, Pimpinelli N. Melanoma density and relationship with the distribution of melanocytic naevi in an Italian population: a GIPMe study--the Italian multidisciplinary group on melanoma. Melanoma Res. 2015;25:80–87. doi: 10.1097/CMR.0000000000000113. [DOI] [PubMed] [Google Scholar]
  • 4.Echeverria B, Botella-Estrada R, Serra-Guillen C, Martorell A, Traves V, Requena C, Sanmartin O, Llombart B, Guillen C, Nagore E. [Increased risk of developing a second primary cutaneous nevus-associated melanoma in patients previously diagnosed with the disease]. [Article in Spanish] Actas Dermosifiliogr. 2010;101:710–716. [PubMed] [Google Scholar]
  • 5.Bulliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer. 2000;85:627–632. doi: 10.1002/(sici)1097-0215(20000301)85:5<627::aid-ijc5>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  • 6.Bulliard JL, De Weck D, Fisch T, Bordoni A, Levi F. Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. Ann Oncol. 2007;18:789–794. doi: 10.1093/annonc/mdl490. [DOI] [PubMed] [Google Scholar]
  • 7.Caini S, Gandini S, Sera F, Raimondi S, Fargnoli MC, Boniol M, Armstrong BK. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer. 2009;45:3054–3063. doi: 10.1016/j.ejca.2009.05.009. [DOI] [PubMed] [Google Scholar]
  • 8.Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer. 1995;75:2492–2498. doi: 10.1002/1097-0142(19950515)75:10<2492::aid-cncr2820751015>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  • 9.Kvaskoff M, Pandeya N, Green AC, Perry S, Baxter C, Davis MB, Mortimore R, Westacott L, Wood D, Triscott J, Williamson R, Whiteman DC. Site-specific determinants of cutaneous melanoma: a case-case comparison of patients with tumors arising on the head or trunk. Cancer Epidemiol Biomarkers Prev. 2013;22:2222–2231. doi: 10.1158/1055-9965.EPI-13-0475. [DOI] [PubMed] [Google Scholar]
  • 10.Naldi L, Adamoli L, Fraschini D, Corbetta A, Imberti L, Reseghetti A, Reciputo A, Rossi E, Cainelli T, Masera G. Number and distribution of melanocytic nevi in individuals with a history of childhood leukemia. Cancer. 1996;77:1402–1408. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1402::AID-CNCR27>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  • 11.Pfahlberg A, Uter W, Kraus C, Wienecke WR, Reulbach U, Kolmel KF, Gefeller O. Monitoring of nevus density in children as a method to detect shifts in melanoma risk in the population. Prev Med. 2004;38:382–387. doi: 10.1016/j.ypmed.2003.11.015. [DOI] [PubMed] [Google Scholar]
  • 12.Schuurman MS, de Waal AC, Thijs EJ, van Rossum MM, Kiemeney LA, Aben KK. Risk factors for second primary melanoma among Dutch melanoma patients. Br J Dermatol. 2017;176:971–978. doi: 10.1111/bjd.15024. [DOI] [PubMed] [Google Scholar]
  • 13.Wachsmuth RC, Turner F, Barrett JH, Gaut R, Randerson-Moor JA, Bishop DT, Bishop JA. The effect of sun exposure in determining nevus density in UK adolescent twins. J Invest Dermatol. 2005;124:56–62. doi: 10.1111/j.0022-202X.2004.23548.x. [DOI] [PubMed] [Google Scholar]
  • 14.Gallagher RP, Rivers JK, Yang CP, McLean DI, Coldman AJ, Silver HK. Melanocytic nevus density in Asian, Indo-Pakistani, and white children: the Vancouver Mole Study. J Am Acad Dermatol. 1991;25:507–512. doi: 10.1016/0190-9622(91)70231-p. [DOI] [PubMed] [Google Scholar]
  • 15.Carli P, Naldi L, Lovati S, La Vecchia C. The density of melanocytic nevi correlates with constitutional variables and history of sunburns: a prevalence study among Italian schoolchildren. Int J Cancer. 2002;101:375–379. doi: 10.1002/ijc.10629. [DOI] [PubMed] [Google Scholar]
  • 16.Purdue MP, From L, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR, Klar NS, Marrett LD. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2005;14:2015–2022. doi: 10.1158/1055-9965.EPI-05-0097. [DOI] [PubMed] [Google Scholar]
  • 17.Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, Zone JJ, Skolnick MH. Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. J Natl Cancer Inst. 1991;83:1726–1733. doi: 10.1093/jnci/83.23.1726. [DOI] [PubMed] [Google Scholar]
  • 18.Gibbs P, Brady BM, Robinson WA. The genes and genetics of malignant melanoma. J Cutaneous Med Surg. 2002;6:229–235. doi: 10.1007/s10227-001-0037-6. [DOI] [PubMed] [Google Scholar]
  • 19.Gallagher RP, Rivers JK, Lee TK, Bajdik CD, McLean DI, Coldman AJ. Broad-spectrum sunscreen use and the development of new nevi in white children: a randomized controlled trial. JAMA. 2000;283:2955–2960. doi: 10.1001/jama.283.22.2955. [DOI] [PubMed] [Google Scholar]
  • 20.Barrett JH, Gaut R, Wachsmuth R, Bishop JA, Bishop DT. Linkage and association analysis of nevus density and the region containing the melanoma gene CDKN2A in UK twins. Br J Cancer. 2003;88:1920–1924. doi: 10.1038/sj.bjc.6600904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA. Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. J Invest Dermatol. 2008;128:2122–2125. doi: 10.1038/jid.2008.51. [DOI] [PubMed] [Google Scholar]
  • 22.Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski WE, Zone JJ, Leachman SA. Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol. 2004;123:576–582. doi: 10.1111/j.0022-202X.2004.23312.x. [DOI] [PubMed] [Google Scholar]
  • 23.Purdue MP, From L, Kahn HJ, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR, Klar NS, Marrett LD. Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma. Int J Cancer. 2005;117:486–493. doi: 10.1002/ijc.21196. [DOI] [PubMed] [Google Scholar]
  • 24.Welkovich B, Landthaler M, Schmoeckel C, Braun-Falco O. [The number and distribution of nevus cell nevi in patients with malignant melanoma]. [Article in German] Hautarzt. 1989;40:630–635. [PubMed] [Google Scholar]
  • 25.Rodenas JM, Delgado-Rodriguez M, Farinas-Alvarez C, Herranz MT, Serrano S. Melanocytic nevi and risk of cutaneous malignant melanoma in southern Spain. Am J Epidemiol. 1997;145:1020–1029. doi: 10.1093/oxfordjournals.aje.a009058. [DOI] [PubMed] [Google Scholar]
  • 26.Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA, Kirkpatrick C, Mack T, Bishop JN, et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer. 2009;124:937–944. doi: 10.1002/ijc.24011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Randi G, Naldi L, Gallus S, Di Landro A, La Vecchia C. Number of nevi at a specific anatomical site and its relation to cutaneous malignant melanoma. J Invest Dermatol. 2006;126:2106–2110. doi: 10.1038/sj.jid.5700334. [DOI] [PubMed] [Google Scholar]
  • 28.Rieger E, Soyer HP, Garbe C, Buttner P, Kofler R, Weiss J, Stocker U, Kruger S, Roser M, Weckbecker J, Panizzon R, Bahmer F, Tilgen W, et al. Overall and site-specific risk of malignant melanoma associated with nevus counts at different body sites: a multicenter case-control study of the German Central Malignant-Melanoma Registry. Int J Cancer. 1995;62:393–397. doi: 10.1002/ijc.2910620406. [DOI] [PubMed] [Google Scholar]
  • 29.Nagore E, Botella-Estrada R, Requena C, Serra-Guillen C, Martorell A, Hueso L, Llombart B, Sanmartin O, Guillen C. [Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site]. [Article in Spanish] Actas Dermosifiliogr. 2009;100:205–211. [PubMed] [Google Scholar]
  • 30.Montero I, Requena C, Traves V, Garcia-Casado Z, Kumar R, Nagore E. Age-related characteristics of cutaneous melanoma in a Spanish Mediterranean population. Int J Dermatol. 2015;54:778–784. doi: 10.1111/ijd.12496. [DOI] [PubMed] [Google Scholar]
  • 31.Pena-Vilabelda MM, Garcia-Casado Z, Requena C, Traves V, Lopez-Guerrero JA, Guillen C, Kumar R, Nagore E. Clinical characteristics of patients with cutaneous melanoma according to variants in the melanocortin 1 receptor gene. Actas Dermosifiliogr. 2014;105:159–171. doi: 10.1016/j.ad.2013.10.001. [DOI] [PubMed] [Google Scholar]
  • 32.Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122:342–348. doi: 10.1046/j.0022-202X.2004.22225.x. [DOI] [PubMed] [Google Scholar]
  • 33.Bataille V, Sasieni P, Grulich A, Swerdlow A, McCarthy W, Hersey P, Newton Bishop JA, Cuzick J. Solar keratoses: a risk factor for melanoma but negative association with melanocytic naevi. Int J Cancer. 1998;78:8–12. doi: 10.1002/(sici)1097-0215(19980925)78:1<8::aid-ijc2>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 34.Kvaskoff M, Pandeya N, Green AC, Perry S, Baxter C, Davis MB, Mortimore R, Westacott L, Wood D, Triscott J, Williamson R, Whiteman DC. Solar elastosis and cutaneous melanoma: a site-specific analysis. Int J Cancer. 2015;136:2900–2911. doi: 10.1002/ijc.29335. [DOI] [PubMed] [Google Scholar]
  • 35.DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916;17:683–871. [Google Scholar]
  • 36.Wallace AB. The exposure treatment of burns. 1951;1:501–504. doi: 10.1016/s0140-6736(51)91975-7. [DOI] [PubMed] [Google Scholar]
  • 37.Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC. MC1R germline variants confer risk for BRAF-mutant melanoma. Science. 2006;313:521–522. doi: 10.1126/science.1127515. [DOI] [PubMed] [Google Scholar]
  • 38.Garcia-Casado Z, Traves V, Banuls J, Niveiro M, Gimeno-Carpio E, Jimenez-Sanchez AI, Moragon M, Onrubia JA, Oliver V, Kumar R, Nagore E. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma. Br J Dermatol. 2015;172:1128–1131. doi: 10.1111/bjd.13521. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oncotarget-08-98876-s001.pdf (1,000.8KB, pdf)

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES